Corbus Pharmaceuticals Holdings, Inc.(CRBP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CRBP Corbus Pharmaceuticals Holdings, Inc.

休市中 08-07 16:00:00 EDT

10.17

+0.43

+4.41%

盘后9.77

-0.40-3.93%

19:34 EDT

最高10.23	最低9.74	成交量35.71万
今开9.74	昨收9.74	日振幅5.03%
总市值1.88亿	流通市值1.69亿	总股本1,853万
成交额358.23万	换手率2.15%	流通股本1,657万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CRBP","market":"US","secType":"STK","nameCN":"Corbus Pharmaceuticals Holdings, Inc.","latestPrice":10.17,"timestamp":1786132800000,"preClose":9.74,"halted":0,"volume":357127,"hourTrading":{"tag":"盘后","latestPrice":9.77,"preClose":10.17,"latestTime":"19:34 EDT","volume":4713,"amount":46866.262,"timestamp":1786145647861,"change":-0.4,"changeRate":-0.039331,"amplitude":0.039331},"delay":0,"changeRate":0.0441478439425051,"floatShares":16573985,"shares":18527795,"eps":-5.660431,"marketStatus":"休市中","change":0.43,"latestTime":"08-07 16:00:00 EDT","open":9.74,"high":10.23,"low":9.74,"amount":3582296.296125,"amplitude":0.050308,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.660431,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786348800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":9.74,"postHourTrading":{"tag":"盘后","latestPrice":9.77,"preClose":10.17,"latestTime":"19:34 EDT","volume":4713,"amount":46866.262,"timestamp":1786145647861,"change":-0.4,"changeRate":-0.039331,"amplitude":0.039331},"volumeRatio":1.5627576312822686,"impliedVol":1.1156,"impliedVolPercentile":0.6056},"requestUrl":"/m/hq/s/CRBP","defaultTab":"news","newsList":[{"id":"1190665325","title":"Corbus Pharmaceuticals宣布：CRB-913治疗肥胖症Canyon-1研究完成最后一名患者末次访视","url":"https://stock-news.laohu8.com/highlight/detail?id=1190665325","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190665325?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:31","pubTimestamp":1785846677,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals于今日正式披露，其针对肥胖症治疗的CRB-913所开展的Canyon-1研究，已顺利完成最后一名患者的末次访视。所有参与研究的受试者，均已完成按照既定方案要求的所有访视及评估流程。Corbus管理层对此表示，这一成果的达成，为后续的数据分析工作奠定了坚实基础。Corbus的CRB-913作为一种新型候选药物，其临床数据的安全性及有效性表现，备受市场与投资者的关注。下一步，Corbus将进入更为关键的数据库锁定与统计分析阶段，为最终向监管机构提交申请铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172107419","title":"Corbus Pharmaceuticals 获FDA许可，启动CRB-701治疗二线口咽癌的Tempo-1注册研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1172107419","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172107419?lang=zh_cn&edition=full","pubTime":"2026-07-28 20:01","pubTimestamp":1785240069,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals宣布，已获得美国食品药品监督管理局（FDA）的批准，得以启动一项名为Tempo-1的注册研究。该研究旨在评估CRB-701在二线口咽癌患者中的疗效与安全性。这一里程碑式的进展，标志着公司在肿瘤治疗领域的管线迈入关键阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167304047","title":"CRBP旗下CRB-701整体安全性良好，停药率低于3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167304047","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167304047?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:04","pubTimestamp":1779793453,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc.（CRBP）公布的其候选药物CRB-701的临床数据显示，该药物整体表现出良好的安全性和耐受性。\n在临床试验中，因不良事件导致的停药率被控制在3%以下，这一数据为后续开发提供了积极的安全信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146023842","title":"Corbus Pharmaceuticals公布CRB-701药物1/2期临床试验最新数据，在二线治疗口咽癌与宫颈癌中展现强劲活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1146023842","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146023842?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:03","pubTimestamp":1779793400,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals披露了其候选药物CRB-701的1/2期临床试验最新数据。这些更新结果显示，该药物在治疗二线口咽癌和宫颈癌患者中，表现出显著的抗肿瘤活性。\n临床数据揭示了CRB-701在目标患者群体中的积极疗效信号，为后续开发提供了有力支持。这一进展凸显了该疗法在应对这些癌症类型方面的潜力。\n公司基于这些令人鼓舞的结果，将继续推进CRB-701的临床开发计划。后续研究将致力于进一步评估其安全性与有效性，以期为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198768990","title":"Corbus Pharmaceuticals 计划今夏启动CRB-701用于二线头颈癌的注册研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1198768990","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198768990?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:03","pubTimestamp":1779365009,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc. 宣布，将于今年夏季启动一项针对CRB-701在二线头颈部鳞状细胞癌治疗中的注册研究。此举标志着该公司在推进其核心候选药物方面迈出了关键一步，旨在满足该治疗领域未满足的临床需求。\n这项即将开展的注册研究旨在评估CRB-701在特定患者群体中的疗效与安全性，为后续的监管申报提供关键数据支持。头颈癌领域存在巨大的医疗需求，新疗法的开发备受关注。\n公司选择在夏季启动研究，展现了其加速研发进程的战略部署。随着研究的推进，相关临床数据将成为市场关注的焦点，并可能对公司的未来发展产生重要影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197712302","title":"Corbus Pharmaceuticals任命Nishant Saxena为首席商务官，并计划召开2026年ASCO会议前CRB-701数据电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1197712302","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197712302?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:01","pubTimestamp":1779364887,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc.  宣布，已任命Nishant Saxena为公司首席商务官。与此同时，该公司还安排了一场电话会议，计划在2026年美国临床肿瘤学会年会之前，重点讨论其候选药物CRB-701的相关数据。会议的核心议题将围绕CRB-701的临床数据展开，该药物是公司研发管线中的重要资产。此次沟通旨在向投资者和分析师更新该候选药物的最新进展，并为即将到来的2026年ASCO年会进行预热。通过这一系列举措，Corbus Pharmaceuticals展现了其在推进临床项目与加强团队建设方面的双重努力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108601446","title":"Guggenheim首予Corbus Pharmaceuticals买入评级 目标价45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108601446","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108601446?lang=zh_cn&edition=full","pubTime":"2026-04-29 11:17","pubTimestamp":1777432638,"startTime":"0","endTime":"0","summary":"投资机构Guggenheim近日首次覆盖生物制药公司Corbus Pharmaceuticals Holdings Inc，给予\"买入\"评级，并设定45美元的目标股价。\n此次覆盖标志着华尔街对这家专注于炎症和肿瘤领域创新疗法研发的企业投下信任票。目标价的设定也反映出分析师对该司未来增长潜力的积极预期。\nCorbus Pharmaceuticals目前正在推进多项临床阶段候选药物，其核心产品线针对纤维化疾病和癌症治疗领域。Guggenheim的买入评级或将进一步提升市场对该公司的关注度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129593717","title":"Corbus Pharmaceuticals宣布Canyon-1研究中最后一名患者首次接受CRB-913肥胖治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1129593717","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129593717?lang=zh_cn&edition=full","pubTime":"2026-04-14 20:03","pubTimestamp":1776168237,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc. 已宣布，在其针对肥胖治疗的CRB-913药物Canyon-1研究中，最后一名患者完成了首次访视。这一进展标志着该研究的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134165905","title":"Corbus Pharmaceuticals Holdings Inc 将继续与FDA沟通以敲定注册研究方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1134165905","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134165905?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563280,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings Inc (CRBP) 宣布，公司计划持续推进与美国食品药品监督管理局（FDA）的互动，旨在最终确定其关键注册研究的试验方案。这一步骤对于公司后续的新药申报及商业化进程至关重要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193537309","title":"Corbus Pharmaceuticals与FDA就CRB-701在二线头颈癌及宫颈癌的注册路径达成广泛共识","url":"https://stock-news.laohu8.com/highlight/detail?id=1193537309","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193537309?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563275,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings, Inc. 宣布，其与FDA就CRB-701在二线头颈鳞状细胞癌及宫颈癌的注册路径达成了广泛共识。这一进展标志着公司在推进该候选药物治疗方案方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613429198","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 早盘股价大跌5.08%报7.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613429198","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2613429198?lang=zh_cn&edition=full","pubTime":"2026-02-20 23:16","pubTimestamp":1771600602,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日23时16分，Corbus Pharmaceuticals Holdings, Inc.股票出现异动，股价急速跳水5.08%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.69%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精密肿瘤公司，致力于通过将科学方法引入了解的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220231642a4b6ca48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260220231642a4b6ca48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180008347","title":"Corbus制药公司第四季度每股收益$(0.78)优于预期的$(1.20)","url":"https://stock-news.laohu8.com/highlight/detail?id=1180008347","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180008347?lang=zh_cn&edition=full","pubTime":"2025-03-11 21:00","pubTimestamp":1741698029,"startTime":"0","endTime":"0","summary":"Corbus制药公司第四季度每股收益$(0.78)优于预期的$(1.20)以上内容来自Benzinga Earnings专栏，原文如下：Corbus Pharmaceuticals Q4 EPS $(0.78) Beats $(1.20) Estimate","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corbus制药公司第四季度每股收益$(0.78)优于预期的$(1.20)","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516637872","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637872","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516637872?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:03","pubTimestamp":1741014224,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时03分，Corbus Pharmaceuticals Holdings, Inc.股票出现异动，股价急速下跌5.10%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230345a25d49c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303230345a25d49c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514320289","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 股价大涨7.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514320289?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:31","pubTimestamp":1740753065,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时31分，Corbus Pharmaceuticals Holdings, Inc.股票出现波动，股价大幅上涨7.50%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.02%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502282231059896796e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502282231059896796e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513372082","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 快速下跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513372082","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513372082?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:54","pubTimestamp":1740408851,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时54分，Corbus Pharmaceuticals Holdings, Inc.股票出现异动，股价急速下跌5.26%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.17%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225411962e9e81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225411962e9e81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512439953","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 下午盘快速下挫5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512439953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512439953?lang=zh_cn&edition=full","pubTime":"2025-02-20 04:07","pubTimestamp":1739995653,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日04时07分，Corbus Pharmaceuticals Holdings, Inc.股票出现波动，股价快速跳水5.12%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.53%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502200407349629027c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502200407349629027c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511577852","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511577852","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511577852?lang=zh_cn&edition=full","pubTime":"2025-02-14 04:55","pubTimestamp":1739480140,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日04时55分，Corbus Pharmaceuticals Holdings, Inc.股票出现异动，股价急速上涨5.10%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体涨幅为1.11%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214045541a244f671&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214045541a244f671&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510338178","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 早盘股价大跌5.11%报9.28美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510338178","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510338178?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:04","pubTimestamp":1739286285,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时04分，Corbus Pharmaceuticals Holdings, Inc.股票出现异动，股价急速跳水5.11%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体跌幅为1.36%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112304459881c3a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502112304459881c3a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510559258","title":"HC Wainwright & Co.：重申Corbus Pharmaceuticals(CRBP.US)评级，由买入调整至买入评级, 目标价由80.00美元调整至75.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510559258","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510559258?lang=zh_cn&edition=full","pubTime":"2025-02-10 19:54","pubTimestamp":1739188451,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Corbus Pharmaceuticals(CRBP.US)评级，由买入调整至买入评级, 目标价由80.00美元调整至75.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/10195448056207.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["CRBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509728306","title":"Corbus Pharmaceuticals Holdings, Inc.盘中异动 急速下跌5.09%报10.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509728306","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509728306?lang=zh_cn&edition=full","pubTime":"2025-02-07 23:44","pubTimestamp":1738943098,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日23时44分，Corbus Pharmaceuticals Holdings, Inc.股票出现异动，股价大幅下挫5.09%。Corbus Pharmaceuticals Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Corbus Pharmaceuticals Holdings, Inc.公司简介：Corbus Pharmaceuticals Holdings Inc 是一家拥有多元化产品组合的精准肿瘤学公司，致力于通过将科学方法引入人们熟知的生物途径来帮助人们战胜严重疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207234458987dbb21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207234458987dbb21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corbuspharma.com","stockEarnings":[{"period":"1week","weight":0.1338},{"period":"1month","weight":0.0649},{"period":"3month","weight":-0.0721},{"period":"6month","weight":0.2989},{"period":"1year","weight":0.13},{"period":"ytd","weight":0.2494}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Corbus Pharmaceuticals Holdings, Inc.于2009年4月24日根据特拉华州法律注册成立。Corbus是一家精准肿瘤学公司，拥有多元化的产品组合，致力于通过将创新的科学方法引入已被广泛理解的生物途径，帮助人们战胜严重疾病。该公司的管线由两种针对实体瘤的实验药物组成：CRB-701，一种下一代抗体药物偶联物，靶向Nectin-4在癌细胞上的表达以释放细胞毒性有效载荷，CRB-601，一种抗整合素单克隆抗体，可阻断癌细胞上表达的TGFβ的激活。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.363358},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.048678},{"month":3,"riseRate":0.636364,"avgChangeRate":0.197993},{"month":4,"riseRate":0.545455,"avgChangeRate":0.046477},{"month":5,"riseRate":0.583333,"avgChangeRate":0.055971},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.044414},{"month":7,"riseRate":0.25,"avgChangeRate":-0.049826},{"month":8,"riseRate":0.666667,"avgChangeRate":0.098848},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.086452},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.124298},{"month":11,"riseRate":0.727273,"avgChangeRate":0.130055},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.132264}],"exchange":"NASDAQ","name":"Corbus Pharmaceuticals Holdings, Inc.","nameEN":"Corbus Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corbus Pharmaceuticals Holdings, Inc.(CRBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Corbus Pharmaceuticals Holdings, Inc.(CRBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Corbus Pharmaceuticals Holdings, Inc.,CRBP,Corbus Pharmaceuticals Holdings, Inc.股票,Corbus Pharmaceuticals Holdings, Inc.股票老虎,Corbus Pharmaceuticals Holdings, Inc.股票老虎国际,Corbus Pharmaceuticals Holdings, Inc.行情,Corbus Pharmaceuticals Holdings, Inc.股票行情,Corbus Pharmaceuticals Holdings, Inc.股价,Corbus Pharmaceuticals Holdings, Inc.股市,Corbus Pharmaceuticals Holdings, Inc.股票价格,Corbus Pharmaceuticals Holdings, Inc.股票交易,Corbus Pharmaceuticals Holdings, Inc.股票购买,Corbus Pharmaceuticals Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corbus Pharmaceuticals Holdings, Inc.(CRBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Corbus Pharmaceuticals Holdings, Inc.(CRBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}